Generalized anxiety disorder (GAD) is a condition where a person often feels very worried or anxious. Sometimes, the usual treatment with antidepressants (ADT) doesn't work well enough. This study looks at adding a new drug called ABBV-932 to see if it helps better. ABBV-932 is still being tested to see if it's safe and effective for GAD. Participants will either get ABBV-932 or a placebo (a pill that looks like medicine but isn't) along with their regular ADT. There's a 1 in 3 chance of getting the placebo.
About 315 adults with GAD will join this study in the U.S. and Puerto Rico. They will take the study medicine for 6 weeks, followed by a 4-week check-up period. Participants will visit a hospital or clinic regularly for tests and to see how they feel. These visits will include medical checks, blood tests, and questionnaires.
- Study lasts for 10 weeks total, including follow-up.
- Participants may face a higher treatment burden compared to usual care.
- Regular hospital or clinic visits are required for assessments.